NMRC received guidance from the FDA

NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC

-Two human phase II clinical trials to be conducted in 2021

-One trial will focus on the ability of the hyperimmune product to protect volunteers against moderate to severe campylobacteriosis

-The second trial will focus on ETEC infections

finance.yahoo.com/ne...earch-100010355.html